secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALUMIS INC. (ALMS)
CIK:        0001847367
Form:       8-K
Filed at:   2025-03-19T23:59:59+00:00
Accession:  0001847367-25-000010
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alumis 2024 net loss $294.2M, cash $288.3M; ACELYRIN merger expected Q2 2025
----------------------------------------------------------------------------

- Net loss of $294.2M in 2024 vs $155.0M in 2023; R&D expenses rose to $265.6M from $137.7M.
- Cash, cash equivalents and marketable securities of $288.3M as of Dec 31, 2024.
- All-stock merger with ACELYRIN; pro forma cash ~$737M; Alumis stockholders to own ~55% on diluted basis.
- Phase 3 ESK-001 psoriasis topline data expected Q1 2026; Phase 2 MS trial for A-005 to start 2H 2025.
- Appointed Jack Danilkowicz as CCO and Sara Klein as CLO to bolster late-stage capabilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847367/000184736725000010/0001847367-25-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847367/000184736725000010/tmb-20250319x8k.htm
  HTML page:      https://secwatch.observer/filing/0001847367-25-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer